Danaher Corporation (NYSE:DHR) Position Raised by DLK Investment Management LLC

DLK Investment Management LLC lifted its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 8.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,021 shares of the conglomerate's stock after purchasing an additional 1,820 shares during the period. Danaher comprises 2.1% of DLK Investment Management LLC's portfolio, making the stock its 22nd largest position. DLK Investment Management LLC's holdings in Danaher were worth $4,924,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in DHR. FAS Wealth Partners Inc. boosted its position in Danaher by 20.6% in the 4th quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock valued at $2,203,000 after buying an additional 1,639 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Danaher by 3.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,066,755 shares of the conglomerate's stock worth $933,524,000 after acquiring an additional 135,047 shares in the last quarter. Camden National Bank boosted its holdings in Danaher by 285.0% in the fourth quarter. Camden National Bank now owns 7,227 shares of the conglomerate's stock valued at $1,659,000 after purchasing an additional 5,350 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Danaher by 11.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock valued at $1,303,163,000 after purchasing an additional 579,046 shares in the last quarter. Finally, Terra Alpha Investments LLC purchased a new stake in Danaher during the 4th quarter worth approximately $3,068,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman now owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the transaction, the executive vice president now directly owns 15,179 shares in the company, valued at $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Stifel Nicolaus raised shares of Danaher from a "hold" rating to a "buy" rating and set a $260.00 price target for the company in a research report on Friday, March 14th. Argus decreased their price objective on shares of Danaher from $260.00 to $240.00 in a report on Wednesday, April 23rd. Deutsche Bank Aktiengesellschaft cut their target price on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Wells Fargo & Company reduced their price target on shares of Danaher from $240.00 to $210.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 23rd. Finally, Robert W. Baird lowered their price objective on Danaher from $231.00 to $225.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $248.61.

Danaher Stock Performance

DHR stock traded up $0.88 during mid-day trading on Thursday, reaching $201.88. The company had a trading volume of 5,562,250 shares, compared to its average volume of 3,493,100. Danaher Corporation has a one year low of $171.00 and a one year high of $281.70. The stock has a market capitalization of $144.48 billion, a P/E ratio of 39.20, a P/E/G ratio of 2.77 and a beta of 0.77. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. The stock's 50-day simple moving average is $194.31 and its two-hundred day simple moving average is $209.00.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. The business had revenue of $5.74 billion for the quarter, compared to analysts' expectations of $5.58 billion. Danaher had a net margin of 15.81% and a return on equity of 10.80%. Research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.63%. Danaher's dividend payout ratio is presently 24.85%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.